Medicinal chemist support services
Ended Purchase Order Awarded Last action
- Contract number
- HT942524P0111
- Awardee
-
SIA Partners U.s., Inc. UEI M7H6L5MK9MN8
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $25,677
Award facts
- Opportunity
-
- Medicinal Chemist Services in support of USAMRIID Solicitation · HT942524R0107 · Posted Jun 25, 2024
- Contract value 100% obligated
- $25,676.96 Current and potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- Contracting staff
- NAICS code
- 621511 Medical Laboratories
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Frederick, MD 21702, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | -$29,323 | |
| Terminate for Convenience | $0 | |
| Original award | $55,000 |
About this award
The Defense Health Agency awarded a $25,676.96 firm fixed-price purchase order to SIA Partners U.S., Inc. (doing business as Latham Biopharm Group) on September 25, 2024, for medicinal chemist support services. The contract, which runs through September 30, 2027, fulfills a solicitation issued by the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) seeking non-personal medicinal chemist consulting services to support antiviral therapeutics development. The work will be performed in Frederick, Maryland, and represents a continuation of Latham Biopharm Group's existing relationship with the Department of Defense in providing advanced scientific consulting to federal agencies in the pharmaceutical and biotechnology sectors.
This award was not set aside for any specific business type and reflects Latham Biopharm Group's demonstrated expertise in medicinal chemistry and preclinical development services. The contractor brings significant relevant experience through its $30 million Indefinite Delivery Contract with the National Institute of Allergy and Infectious Diseases, which covers product development planning, analytical assay development, and regulatory support activities. Latham Biopharm Group's established track record supporting infectious disease therapeutics development across multiple federal agencies positions it to effectively deliver the specialized medicinal chemistry expertise required by USAMRIID's antiviral therapeutic development initiatives.
Quick answers
Who was awarded contract HT942524P0111?
HT942524P0111 was awarded to SIA Partners U.s., Inc. by Defense Health Agency (Department of Defense) on September 25, 2024.
How much is contract HT942524P0111 worth?
The government has obligated $25,677 on HT942524P0111.
Was contract HT942524P0111 competed?
The extent of competition for HT942524P0111 was competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award